A Phase 1, Open-Label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants with B-cell Mediated Autoimmune Disorders

Grants and Contracts Details

StatusActive
Effective start/end date12/20/24 → 12/20/26

Funding

  • TG Therapeutics Incorporated: $2.00